475 related articles for article (PubMed ID: 24225201)
41. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
[TBL] [Abstract][Full Text] [Related]
42. Is There a Role for Ivabradine in the Contemporary Management of Patients with Chronic Heart Failure in Academic and Community Heart Failure Clinics in Canada?
Roth S; Fernando C; Azeem S; Moe GW
Adv Ther; 2017 Jun; 34(6):1340-1348. PubMed ID: 28432646
[TBL] [Abstract][Full Text] [Related]
43. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
[TBL] [Abstract][Full Text] [Related]
44. Limited role for ivabradine in the treatment of chronic heart failure.
Cullington D; Goode KM; Cleland JG; Clark AL
Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
[TBL] [Abstract][Full Text] [Related]
45. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
46. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
[TBL] [Abstract][Full Text] [Related]
47. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction.
Gallet R; Ternacle J; Damy T; Guendouz S; Bremont C; Seemann A; Gueret P; Dubois-Rande JL; Lim P
Int J Cardiol; 2014 Sep; 176(2):450-5. PubMed ID: 25129291
[TBL] [Abstract][Full Text] [Related]
48. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
49. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
50. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Chow SL; Page RL; Depre C
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
[TBL] [Abstract][Full Text] [Related]
51. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
[TBL] [Abstract][Full Text] [Related]
52. [The efficacy and safety of the combination of β-blocker bisoprolol and if inhibitor I(f) ivabradine in patients with stable angina and chronic obstructive pulmonary disease].
Ageev FT; Makarova GV; Patrusheva IF; Orlova IaA
Kardiologiia; 2010; 50(10):22-6. PubMed ID: 21118175
[TBL] [Abstract][Full Text] [Related]
53. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy of ivabradine in patients with stable angina and comorbid chronic obstructive pulmonary disease].
Khamaeva AA; Belialov FI; Kerzina LV; Berezovskaia OV; Parshukova ED; Zakharova GIu
Kardiologiia; 2012; 52(1):15-9. PubMed ID: 22304347
[TBL] [Abstract][Full Text] [Related]
55. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
Brooks TW; Creekmore FM; Young DC; Asche CV; Oberg B; Samuelson WM
Pharmacotherapy; 2007 May; 27(5):684-90. PubMed ID: 17461703
[TBL] [Abstract][Full Text] [Related]
56. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
Lopatin YM; Cowie MR; Grebennikova AA; Sisakian HS; Pagava ZM; Hayrapetyan HG; Abdullaev TA; Voronkov LG; Chesnikova AI; Tseluyko VI; Tarlovskaya EI; Dadashova GM; Berkinbaev SF; Glezer MG; Koziolova NA; Rakisheva AG; Kipiani ZV; Kurlyanskaya AK
Int J Cardiol; 2018 Jun; 260():113-117. PubMed ID: 29622423
[TBL] [Abstract][Full Text] [Related]
57. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure.
Rusinaru D; Saaidi I; Godard S; Mahjoub H; Battle C; Tribouilloy C
Am J Cardiol; 2008 Feb; 101(3):353-8. PubMed ID: 18237599
[TBL] [Abstract][Full Text] [Related]
58. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
Foster JL; Bobadilla RV
J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
60. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
